This form of immune tolerance induction is now safer, more reliably efficacious and better

understood than when it was first formally described in 1911. In this paper the authors aim to summarize the current state of the art in immunotherapy in the treatment of inhalant, venom and drug allergies, with specific reference to its practice in the United Kingdom. A practical approach has been taken, with reference to current evidence and guidelines, including illustrative protocols and vaccine schedules. A number of novel approaches and techniques are likely to change considerably the way in which we select and treat allergy patients in the coming decade, and these advances are previewed. CDK inhibition On 10 June 1911, Leonard Noon published the first short description of allergen-specific immunotherapy by injection [1]. His short

paper described increasing tolerance to conjunctival challenge testing with grass pollen extract. His work was completed by Freeman [2], who published a clinical description of improved hay fever symptoms in September of the same year. Between them, these papers described the hypothesis underpinning allergen immunotherapy, the production and standardization of pollen extracts, the use of subcutaneous injections, with short interval up-dosing and longer interval Ivacaftor datasheet maintenance, and adverse reaction due to overdose. They suggested confirmation of sensitization (by conjunctival challenge) prior to commencing therapy, titration of the starting dose, the choice of the single pollen Phleum pratense from a selection of grass pollen species, and also stated

that efficacy is proportional to the duration of prophylactic therapy. At face value it could be argued that these concepts have Unoprostone not changed in the last 100 years. However, the practice of allergen immunotherapy is now supported by a wealth of well-controlled studies, and novel formulations and routes of administration have been investigated. Nonetheless, the gold standard procedure of subcutaneous immunotherapy with P. pratense for hay fever remains alarmingly similar to that described a century ago. This review of allergen immunotherapy in the treatment of inhalant, venom and drug allergies will focus on patient selection and modalities of administration of this therapy, with specific emphasis on the practicalities of the safe delivery of this service in a specialist centre. Allergic rhinoconjuctivitis can be treated effectively with immunotherapy, as demonstrated in recent systematic reviews [3–5]. A wide range of aeroallergens, including pollens, house dust mite, animal danders, mould spores and some occupational allergens have been identified as causing allergic airways disease. Standardized allergen extracts are available and the treatment is currently administered either as subcutaneous injection immunotherapy (SCIT) or sublingual immunotherapy (SLIT), and these are discussed in the following sections. Indications.  Careful patient selection is paramount.